A Study Investigating the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Olamkicept in Healthy Persons
- Conditions
- Inflammatory Gastrointestinal Diseases
- Interventions
- Drug: PlaceboDrug: Olamkicept Part BDrug: Olamkicept Part A
- Registration Number
- NCT06298032
- Lead Sponsor
- Ferring Pharmaceuticals
- Brief Summary
Interleukin (IL)-6 is a cytokine produced in response to infection and tissue damage. IL-6 is believed to act as a key mediator in chronic inflammation and autoimmune diseases such as inflammatory bowel diseases. IL-6 is known to be involved in at least two distinct signalling pathways, classical and trans-signalling. The hypothesis is that classical signalling by IL-6 infers some beneficial effects (e.g. on gut barrier function), while excessive IL-6 trans-signalling may have detrimental effects. Olamkicept (FE 999301) has been shown in vitro to be a selective IL-6 trans-signalling inhibitor, and administered at lower doses (600 mg every 2nd week for 12 weeks) it has proven to induce clinical improvement for patients with ulcerative colitis. The aim of this trial is to investigate safety, tolerability, immunogenicity and pharmacokinetics of Olamkicept at higher doses (up to 2400 mg) to support the clinical development program. Our hypothesis is that treatment with higher doses of Olamkicept will result in greater clinical improvement for patients with inflammatory bowel diseases.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 49
- Men ≥18 and ≤45 years of age at screening
- In good health, determined by no clinically significant findings from medical history, physical examination, 12-lead electrocardiogram (ECG), vital signs measurements, and clinical laboratory evaluations, as assessed by the investigator (or designee) at screening and on Day -1
- History of clinically significant medical conditions including, but not limited to, diseases of the renal, hepatic, respiratory, gastrointestinal, cardiovascular, neurological, musculoskeletal, psychiatric, immunological, haematological, oncological, endocrine, and metabolic systems and allergic diseases (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo - Part B Placebo - Placebo - Part A Placebo - Olamkicept - Part B Olamkicept Part B - Olamkicept - Part A Olamkicept Part A -
- Primary Outcome Measures
Name Time Method Change in clinical chemistry from baseline to Day 36 after a single dose infusion From baseline to Day 36 after a single dose infusion Number of participants with clinically significant abnormal findings in clinical chemistry (alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), glucose, calcium, chloride, cholesterol, C-reactive protein, creatinine, estimated glomerular filtration rate (eGFR), gamma-glutamyltransferase, phosphate, potassium, sodium, thyroid stimulating hormone, free triiodothyronine, free thyroxine, total bilirubin, urea (blood urea nitrogen)), from baseline up to and including Day 36 after a single dose infusion (part A of the study)
Change in haemostasis parameters from baseline to Day 64 after multiple dose infusions From baseline up to and including Day 64 after multiple dose infusions Number of participants with clinically significant abnormal findings in haemostasis parameters (activated partial thromboplastin time, prothrombin time) from baseline up to and including Day 64 after multiple dose infusions (part B of the study)
Change in 12-lead electrocardiogram (ECG) from baseline to Day 36 after a single dose infusion From baseline up to and including Day 36 after a single dose infusion Number of participants with clinically significant abnormal findings in ECG (heart rate, PR interval, RR, QRS duration, QT interval, QTc interval, QRS axis), from baseline up to and including Day 36 after a single dose infusion (part A of the study)
Change in 12-lead electrocardiogram (ECG) from baseline to Day 64 after multiple dose infusions From baseline up to and including Day 64 after multiple dose infusions Number of participants with clinically significant abnormal findings in ECG (heart rate, PR interval, RR, QRS duration, QT interval, QTc interval, QRS axis), from baseline up to and including Day 64 after multiple dose infusions (part B of the study)
Change in haematology from baseline to Day 64 after multiple dose infusions From baseline to Day 64 after multiple dose infusions Number of participants with clinically significant abnormal findings in haematology (haematocrit, haemoglobin, mean cellular volume (MCV), mean corpuscular haemoglobin content (MCH), mean corpuscular haemoglobin concentration (MCHC), platelet count, red blood cell count, reticulocytes, white blood cell count with differential count, neutrophils, eosinophils, basophils, lymphocytes, monocytes), from baseline up to and including Day 64 after multiple dose infusions (part B of the study)
Change in clinical chemistry from baseline to Day 64 after multiple dose infusions From baseline up to and including Day 64 after multiple dose infusions Number of participants with clinically significant abnormal findings in clinical chemistry (alanine aminotransferase (ALT), albumin, alkaline phosphatase, aspartate aminotransferase (AST), glucose, calcium, chloride, cholesterol, C-reactive protein, creatinine, estimated glomerular filtration rate (eGFR), gamma-glutamyltransferase, phosphate, potassium, sodium, thyroid stimulating hormone, free triiodothyronine, free thyroxine, total bilirubin, urea (blood urea nitrogen)), from baseline up to and including Day 64 after multiple dose infusions (part B of the study)
Change in urinalysis parameters from baseline to Day 36 after a single dose infusion From baseline to Day 36 after a single dose infusion Number of participants with clinically significant abnormal findings in urinalysis parameters (protein, glucose, bilirubin, pH, nitrite, ketone, urobilinogen, blood, leukocytes, specific gravity) from baseline up to and including Day 36 after a single dose infusion (part A of the study)
Number of treatment-emergent adverse events, including type, intensity, and causality End of trial (up to 64 days) Change in vital signs from baseline to Day 36 after a single dose infusion From baseline up to and including Day 36 after a single dose infusion Number of participants with clinically significant abnormal findings in vital signs (systolic blood pressure, diastolic blood pressure, pulse, body temperature), from baseline up to and including Day 36 after a single dose infusion (part A of the study).
Change in haematology from baseline to Day 36 after a single dose infusion From baseline to Day 36 after a single dose infusion Number of participants with clinically significant abnormal findings in haematology (haematocrit, haemoglobin, mean cellular volume (MCV), mean corpuscular haemoglobin content (MCH), mean corpuscular haemoglobin concentration (MCHC), platelet count, red blood cell count, reticulocytes, white blood cell count with differential count, neutrophils, eosinophils, basophils, lymphocytes, monocytes), from baseline up to and including Day 36 after a single dose infusion (part A of the study)
Change in vital signs from baseline to Day 64 after multiple dose infusions From baseline up to and including Day 64 after multiple dose infusions Number of participants with clinically significant abnormal findings in vital signs (systolic blood pressure, diastolic blood pressure, pulse, body temperature), from baseline up to and including Day 64 after multiple dose infusions (part B of the study)
Change in urinalysis parameters from baseline to Day 64 after multiple dose infusions From baseline up to and including Day 64 after multiple dose infusions Number of participants with clinically significant abnormal findings in urinalysis parameters (protein, glucose, bilirubin, pH, nitrite, ketone, urobilinogen, blood, leukocytes, specific gravity) from baseline up to and including Day 64 after multiple dose infusions (part B of the study)
Change in haemostasis parameters from baseline to Day 36 after a single dose infusion From baseline up to and including Day 36 after a single dose infusion Number of participants with clinically significant abnormal findings in haemostasis parameters (activated partial thromboplastin time, prothrombin time) from baseline up to and including Day 36 after a single dose infusion (part A of the study)
- Secondary Outcome Measures
Name Time Method Single-dose PK of FE 999301: Mean residence time (MRT) From baseline up to and including Day 36 after a single dose infusion Single-dose PK of FE 999301: Area under the concentration-time curve from dosing to infinity (AUCinf) From baseline up to and including Day 36 after a single dose infusion Single-dose PK of FE 999301: Baseline adjusted maximum observed concentration; also referred to as maximum exposure (Cmax) From baseline up to and including Day 36 after a single dose infusion Single-dose PK of FE 999301: Time of maximum observed concentration (tmax) From baseline up to and including Day 36 after a single dose infusion Single-dose PK of FE 999301: Terminal half-life (t1/2) From baseline up to and including Day 36 after a single dose infusion Single-dose PK of FE 999301: Apparent volume of distribution at steady-state (Vss) From baseline up to and including Day 36 after a single dose infusion Single-dose PK of FE 999301: Total clearance (CL) From baseline up to and including Day 36 after a single dose infusion Multiple-dose PK of FE 999301: Observed accumulation index (Rac) From baseline up to and including Day 64 after a multiple dose infusions Multiple-dose PK of FE 999301: Apparent volume of distribution at steady-state (Vss) Day 64 Multiple-dose PK of FE 999301: Baseline adjusted maximum observed concentration; also referred to as maximum exposure (Cmax) From baseline up to and including Day 64 after a multiple dose infusions Multiple-dose PK of FE 999301: Total clearance (CL) From baseline up to and including Day 64 after a multiple dose infusions Multiple-dose PK of FE 999301: Area under concentration-time curve from dosing up to time τ, where τ is the dosing interval (AUCτ) From baseline up to and including Day 64 after a multiple dose infusions Multiple-dose PK of FE 999301: Observed plasma concentration at end of infusion (Ceio) From baseline up to and including Day 64 after a multiple dose infusions Multiple-dose PK of FE 999301: Time of maximum observed concentration (tmax) From baseline up to and including Day 64 after a multiple dose infusions Multiple-dose PK of FE 999301: Terminal half-life (t½) From baseline up to and including Day 64 after a multiple dose infusions Single-dose PK of FE 999301: Area under the concentration-time curve to last measurable concentration (AUClast) From baseline up to and including Day 36 after a single dose infusion Single-dose PK of FE 999301: Observed plasma concentration at end of infusion (AUCeoi) From baseline up to and including Day 36 after a single dose infusion Multiple-dose PK of FE 999301: Area under the concentration-time curve to last measurable concentration (AUClast) From baseline up to and including Day 64 after a multiple dose infusions Multiple-dose PK of FE 999301: Mean residence time (MRT) From baseline up to and including Day 64 after a multiple dose infusions Presence of anti-FE 999301 antibodies on Days 1, 15, and 57 after multiple dose infusions On Days 1, 15, and 57 after multiple dose infusions
Trial Locations
- Locations (1)
Ferring Investigational Site
🇩🇪Berlin, Germany